Company intelligence / Profile preview

成都米子生物医药科技

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Mizi Bio is a preclinical-stage biotechnology company headquartered in Chengdu, China, specializing in the discovery of innovative small molecule therapeutics. The company leverages a proprietary Targeted Protein Degradation (TPD) platform, with a specific focus on Proteolysis-Targeting Chimera (PROTAC) technology. Mizi Bio aims to address "undruggable" protein targets that are implicated in the progression of various cancers and other complex diseases. Founded in 2021, the firm is currently advancing a pipeline of early-stage candidates, including its lead program MZ-001, toward clinical development.

Therapeutic areas: Oncology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Beyond the preview

Go deeper on 成都米子生物医药科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 成都米子生物医药科技.

Explore the full profile